Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
May 31, 2024 08:00 ET
|
Novartis Pharma AG
Phase III ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results; Scemblix® (asciminib) demonstrated superior MMR rates at week 48 vs....
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
May 30, 2024 18:01 ET
|
Novartis Pharma AG
Patients treated with remibrutinib experienced improvements in weekly urticaria activity scores (UAS7) observed as early as Week 1 and sustained to 1 year (Week 52)1Remibrutinib, an oral Bruton’s...
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio
May 25, 2024 06:15 ET
|
Novartis Pharma AG
In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction...
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
May 25, 2024 06:00 ET
|
Novartis Pharma AG
Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical...
Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash
May 16, 2024 05:27 ET
|
Novartis Pharma AG
Novartis secured 79.6 percent acceptance by MorphoSys shareholders during the initial acceptance period, reaching the minimum 65% acceptance thresholdSettlement of the shares tendered during the...
Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA
May 15, 2024 10:00 ET
|
Novartis Pharma AG
Primary results of the Scemblix® ASC4FIRST pivotal Phase III study in first-line Ph+ CML-CP supporting third US FDA Breakthrough Therapy designation, to be detailed in the ASCO Press Program and the...
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
April 24, 2024 00:30 ET
|
Novartis Pharma AG
There is currently no evidence-based treatment for the smallest babies with malaria The CALINA study tested a new ratio and dose of Coartem® (artemether- lumefantrine) to account for metabolic...
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
April 23, 2024 13:42 ET
|
Novartis Pharma AG
Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic...
Novartis erzielt im ersten Quartal ein zweistelliges Umsatzwachstum und steigert die Kerngewinnmarge; Prognose für das Geschäftsjahr 2024 erhöht
April 23, 2024 01:00 ET
|
Novartis Pharma AG
Ad-hoc-Mitteilung gemäss Art. 53 KRDer Nettoumsatz wuchs im ersten Quartal um +11% (kWk1, +10% USD), das operative Kernergebnis verbesserte sich um +22% (kWk, +16% USD)Die wichtigsten...
Novartis, au premier trimestre: croissance à deux chiffres du chiffre d’affaires et expansion de la marge core; hausse des prévisions pour 2024
April 23, 2024 01:00 ET
|
Novartis Pharma AG
Annonce événementielle au sens de l’art. 53 RCRésultats du premier trimestre (T1)Chiffre d’affaires net en hausse de +11% (tcc1, +10% USD) et du résultat opérationnel core, de +22% (tcc, +16% USD) Les...